

Special Issue

Epigenetic Aspects of the Noncoding Genome and the Epithelial–Mesenchymal Transition

Message from the Guest Editors

The aim of this Special Issue is to focus on the role of transcription factors, epigenetic modifications, chromatin remodeling, and noncoding RNAs in the dynamic event referred to as the epithelial to mesenchymal transition (EMT). During physiological and pathological EMT, cells undergo a profound reprogramming, implying regulation of the expression of numerous genes. In this scenario, a crucial role is performed by transcription factors in driving or inhibiting EMT (e.g., SNAIL) as well as by histone modifications, chromatin architecture and, more recently characterized, noncoding RNAs, in particular microRNAs and lncRNAs. Since this dynamic situation allows for the progression of the complex EMT transdifferentiation program, new insights into the characterization of molecular players involved in this process represent a fundamental field of interest for driving future research. Comprehensive reviews and original articles covering this theme are both welcome in this Special Issue.

Guest Editors

Dr. Cecilia Battistelli

Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Roma, Italy

Prof. Marco Tripodi

Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Roma, Italy

Deadline for manuscript submissions

closed (31 August 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/48995

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).